• Explore /
  • Poster
  • / A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update.

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update.

Abstract Video & Slides Poster

Authors

null

Neil Howard Segal

Memorial Sloan Kettering Cancer Center, New York, NY;

Neil Howard Segal , Meredith Pelster , Eugenia Girda , Lawrence Fong , Anthony J. Olszanski , Hyunsil Han , Kerry A. Casey , Siyu Li , Erik Welf , Chieh-I Chen , Dimitris Skokos , Frank A. Seebach , Israel Lowy , Matthew G. Fury , Melissa Divya Mathias , Nehal J. Lakhani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04626635

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS277)

DOI

10.1200/JCO.2023.41.4_suppl.TPS277

Abstract #

TPS277

Poster Bd #

P19

Abstract Disclosures

Similar Posters

First Author: Neil Howard Segal

First Author: Jiajian Liu

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.

Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.

First Author: Aparna Raj Parikh

First Author: Omid Hamid